Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 7, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015. “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while continuing to streamline AVEO’s operations to align with our needs,” said Michael Bailey, president and chief executive

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 22, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled “Effective treatment

Download PDF Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014. “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage products,” said Michael Bailey, president and chief executive officer. “Our approach to realizing this value is to leverage

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 27, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 12, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company’s partnered and proprietary pipeline programs. He will report